FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048797834> ?p ?o ?g. }

• W3048797834 endingPage "177" @default.
• W3048797834 startingPage "172" @default.
• W3048797834 abstract "Purpose To describe the frequency of ocular flares in patients with noninfectious uveitis who were switched from the originator infliximab to a biosimilar infliximab. Design Retrospective case series. Methods All patients with noninfectious uveitis who were switched from the originator infliximab to biosimilar infliximab-abda for nonmedical reasons were reviewed. Patients were excluded if they had less than 3 months of follow-up on either drug. Data included patient demographics, infliximab dosage information, additional immunosuppression medications, and numbers of and times to flares. The main study outcome was frequency of flares, defined as new or worsening inflammatory activity on examination or imaging. Results A total of 17 patients met the inclusion criteria. There were no statistical differences between the duration of follow-up while on the originator and the duration while on the biosimilar infliximab (12.0 vs. 10.1 months, respectively; P = .307). Patients experienced more flares per person-years after switching to infliximab-abda (.92), than on the originator infliximab (0.19; P = .028). Four of the 6 patients (66.7%) who experienced flare after switching to infliximab-abda did so within 90 days. Only 1 patient had flares while on originator infliximab went on to develop a single flare on infliximab-abda. The final normalized dosage for patients who flared and remained on infliximab-abda (1.301 mg/kg/week) was higher than that for those who did not flare (1.186 mg/kg/week) but was not statistically significant (P = .417). Conclusions Patients who were switched to biosimilar infliximab-abda experience more flares than when previously treated with the originator infliximab. Providers should closely observe patients who switch to biosimilar infliximab, especially within the first 90 days. Patients who do have flares after switching may achieve quiescence with increased biosimilar dosage. To describe the frequency of ocular flares in patients with noninfectious uveitis who were switched from the originator infliximab to a biosimilar infliximab. Retrospective case series. All patients with noninfectious uveitis who were switched from the originator infliximab to biosimilar infliximab-abda for nonmedical reasons were reviewed. Patients were excluded if they had less than 3 months of follow-up on either drug. Data included patient demographics, infliximab dosage information, additional immunosuppression medications, and numbers of and times to flares. The main study outcome was frequency of flares, defined as new or worsening inflammatory activity on examination or imaging. A total of 17 patients met the inclusion criteria. There were no statistical differences between the duration of follow-up while on the originator and the duration while on the biosimilar infliximab (12.0 vs. 10.1 months, respectively; P = .307). Patients experienced more flares per person-years after switching to infliximab-abda (.92), than on the originator infliximab (0.19; P = .028). Four of the 6 patients (66.7%) who experienced flare after switching to infliximab-abda did so within 90 days. Only 1 patient had flares while on originator infliximab went on to develop a single flare on infliximab-abda. The final normalized dosage for patients who flared and remained on infliximab-abda (1.301 mg/kg/week) was higher than that for those who did not flare (1.186 mg/kg/week) but was not statistically significant (P = .417). Patients who were switched to biosimilar infliximab-abda experience more flares than when previously treated with the originator infliximab. Providers should closely observe patients who switch to biosimilar infliximab, especially within the first 90 days. Patients who do have flares after switching may achieve quiescence with increased biosimilar dosage." @default.
• W3048797834 created "2020-08-18" @default.
• W3048797834 creator A5000544700 @default.
• W3048797834 creator A5001013908 @default.
• W3048797834 creator A5003115504 @default.
• W3048797834 creator A5022234997 @default.
• W3048797834 creator A5067459056 @default.
• W3048797834 creator A5068014558 @default.
• W3048797834 creator A5072863451 @default.
• W3048797834 date "2021-05-01" @default.
• W3048797834 modified "2023-10-14" @default.
• W3048797834 title "Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis" @default.
• W3048797834 cites W2006142366 @default.
• W3048797834 cites W2018720535 @default.
• W3048797834 cites W2069010656 @default.
• W3048797834 cites W2127655862 @default.
• W3048797834 cites W2414751009 @default.
• W3048797834 cites W2756870797 @default.
• W3048797834 cites W2764082441 @default.
• W3048797834 cites W2765631588 @default.
• W3048797834 cites W2766267906 @default.
• W3048797834 cites W2786897800 @default.
• W3048797834 cites W2898403984 @default.
• W3048797834 cites W2971590475 @default.
• W3048797834 cites W2985705185 @default.
• W3048797834 cites W2985947116 @default.
• W3048797834 doi "https://doi.org/10.1016/j.ajo.2020.08.005" @default.
• W3048797834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32795432" @default.
• W3048797834 hasPublicationYear "2021" @default.
• W3048797834 type Work @default.
• W3048797834 sameAs 3048797834 @default.
• W3048797834 citedByCount "4" @default.
• W3048797834 countsByYear W30487978342021 @default.
• W3048797834 countsByYear W30487978342023 @default.
• W3048797834 crossrefType "journal-article" @default.
• W3048797834 hasAuthorship W3048797834A5000544700 @default.
• W3048797834 hasAuthorship W3048797834A5001013908 @default.
• W3048797834 hasAuthorship W3048797834A5003115504 @default.
• W3048797834 hasAuthorship W3048797834A5022234997 @default.
• W3048797834 hasAuthorship W3048797834A5067459056 @default.
• W3048797834 hasAuthorship W3048797834A5068014558 @default.
• W3048797834 hasAuthorship W3048797834A5072863451 @default.
• W3048797834 hasConcept C126322002 @default.
• W3048797834 hasConcept C141071460 @default.
• W3048797834 hasConcept C17991360 @default.
• W3048797834 hasConcept C203014093 @default.
• W3048797834 hasConcept C2776194053 @default.
• W3048797834 hasConcept C2777138892 @default.
• W3048797834 hasConcept C2777575956 @default.
• W3048797834 hasConcept C59491497 @default.
• W3048797834 hasConcept C71924100 @default.
• W3048797834 hasConceptScore W3048797834C126322002 @default.
• W3048797834 hasConceptScore W3048797834C141071460 @default.
• W3048797834 hasConceptScore W3048797834C17991360 @default.
• W3048797834 hasConceptScore W3048797834C203014093 @default.
• W3048797834 hasConceptScore W3048797834C2776194053 @default.
• W3048797834 hasConceptScore W3048797834C2777138892 @default.
• W3048797834 hasConceptScore W3048797834C2777575956 @default.
• W3048797834 hasConceptScore W3048797834C59491497 @default.
• W3048797834 hasConceptScore W3048797834C71924100 @default.
• W3048797834 hasFunder F4320308320 @default.
• W3048797834 hasFunder F4320308573 @default.
• W3048797834 hasFunder F4320332585 @default.
• W3048797834 hasLocation W30487978341 @default.
• W3048797834 hasOpenAccess W3048797834 @default.
• W3048797834 hasPrimaryLocation W30487978341 @default.
• W3048797834 hasRelatedWork W1981336058 @default.
• W3048797834 hasRelatedWork W1993762334 @default.
• W3048797834 hasRelatedWork W2587157414 @default.
• W3048797834 hasRelatedWork W2774189845 @default.
• W3048797834 hasRelatedWork W2914211697 @default.
• W3048797834 hasRelatedWork W2914532353 @default.
• W3048797834 hasRelatedWork W2924476097 @default.
• W3048797834 hasRelatedWork W3010465489 @default.
• W3048797834 hasRelatedWork W4229777120 @default.
• W3048797834 hasRelatedWork W4385064586 @default.
• W3048797834 hasVolume "225" @default.
• W3048797834 isParatext "false" @default.
• W3048797834 isRetracted "false" @default.
• W3048797834 magId "3048797834" @default.
• W3048797834 workType "article" @default.